CRLF2 antibody
- Known as:
- CRLF2 (anti-)
- Catalog number:
- orb100404
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- CRLF2 antibody
Related genes to: CRLF2 antibody
- Gene:
- CRLF2 NIH gene
- Name:
- cytokine receptor like factor 2
- Previous symbol:
- -
- Synonyms:
- CRL2, TSLPR
- Chromosome:
- Xp22.3 and Yp11.3
- Locus Type:
- gene with protein product
- Date approved:
- 2001-02-06
- Date modifiied:
- 2017-05-12
Related products to: CRLF2 antibody
Related articles to: CRLF2 antibody
- Tuberculosis, caused by , mainly affects the lungs, while asthma is a common chronic respiratory condition often linked with other health issues. Research on the connection between these two diseases is scarce, and their relationship needs more study. - Source: PubMed
Publication date: 2026/05/19
Liu YingxiaLi KunGuan FeifengZhang YuanzhenLi PingYang MinTan HuixingChen CaifenGuo LanLiu ShumeiShi MingWang JianhuaLiang Hancheng - - Source: PubMed
Publication date: 2026/05/05
Mohamed Sara M ASchofield PeterEvans KathrynFriedrich Karl-HeinzChrist DanielBayat NargesLock Richard B - -like ALL is defined by a gene expression signature similar to that of -positive ALL and absence of all genetic subtype-defining aberrations, including the fusion. Within the International BFM Study Group, we assembled and analyzed a cohort of 100 patients (including 97 children) with -like ALL. We describe their diverse genetic landscape, centered around aberrations with frequent disruptions, as previously shown, but including various rare non-/non- gene fusions, and rearrangements of (r). We show that and aberrations do not occur exclusively in this subtype, which hampers its classification based solely on genomic data. We confirm our previous observation of a strong association of the CD27-positive/CD44low-negative immunophenotype with ::(-like) subtype. Compared to -positive ALL, patients with -like ALL are younger, have higher white blood cell counts at diagnosis, and have an inferior early treatment response. While overall survival is comparable, event-free survival is significantly lower in patients with -like ALL, with NCI risk, early treatment response, deletions, and mutations having prognostic relevance. Notably, Down syndrome is highly prevalent and associated with a worse outcome in -like ALL. In conclusion, we provide biological, demographic, and clinical characteristics of the largest -like cohort presented to date. - Source: PubMed
Publication date: 2026/04/17
Zaliova MarketaSchinnerl DagmarBoer Judith MCaye-Eude AurélieRehn JacquelineSchwab ClaireArfeuille ChloéAttarbaschi AndisheBergmann Anke KatharinaFiser Karelde Groot-Kruseman Hester AHaslinger SabrinaInthal AndreaJanotova IvetaLenk LennartMaurer-Granofszky MargaritaNebral KarinPoyer FionaSramkova LucieStary JanStrullu MarionStuchly JanSutton RosemaryVaskova MartinaWinkowska LucieCario GunnarCavé Hélèneden Boer Monique LHarrison ChristineStrehl SabineWhite DeborahTrka JanZuna Jan - The gene, located at chromosome band 11q23, encodes a lysine methyltransferase essential for hematopoietic gene regulation. While rearrangements are common in acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (B-ALL), amplification is rare, occurring in ~1% of AML cases and even less frequently in B-ALL. Given its rarity, understanding amplification in B-ALL is crucial for improving diagnostics and therapy. We report two adult B-ALL cases with amplification. Patient 1, a 58-year-old male, had amplification (6~18 copies in 68.5% of bone marrow cells), a complex karyotype, and a pathogenic variant (c.524G>A, p.Arg175His). He underwent induction chemotherapy but passed away after two months due to complications. Patient 2, a 66-year-old female, had amplification (8~11 copies in 87.5% of peripheral blood cells) and rearrangement, representing the first reported case of Ph-like B-ALL with amplification in an adult. She deteriorated rapidly and died within four days. In addition to these two cases from our cohort, we review nine published cases with amplification in B-ALL, which showed frequent alterations, emphasizing the clinical and genetic characteristics of this aggressive leukemia subtype. These cases highlight the high-risk nature of -amplified B-ALL, particularly in older adults, where prognosis is poor and linked to variants or rearrangement. Our review underscores the need for genetic profiling to improve risk stratification and treatment. Given the limited documented cases, further research is essential to develop better therapeutic strategies for -amplified B-ALL. - Source: PubMed
Publication date: 2026/02/26
Gao MinChen YunjiaBachiashvili KimoVachhani Pankit JJamy OmerHarada ShukoMackinnon Alexander CraigSingh NirupamaRavindran AishwaryaReddy Baleed VishnuCarroll Andrew JMikhail Fady M - Cytokine receptor-like factor 2 rearrangement (CRLF2r), an aberration causing a Philadelphia chromosome-like gene expression profile and a poor prognostic marker in B-cell acute lymphoblastic leukemia (B-ALL), endows relative chemotherapeutic resistance. Extramedullary disease (EMD), including both central nervous system (CNS) and non-CNS involvement, can also be associated with worse outcomes. The relationship between CRLF2r and EMD is unknown. Based on an initial observation of patients with relapsed/refractory (R/R) CRLF2r B-ALL and EMD, a single-center retrospective review was conducted to evaluate the incidence of EMD in patients with CRLF2r B-ALL. Across 177 children, adolescents, and young adults with R/R B-ALL, 21 (11.9%) harbored CRLF2r, of whom 19 (90.5%) had EMD at some point during their treatment course. In contrast, only 78 of the 156 patients (50%) without CRLF2r ever had EMD (P = .0003). In the CRLF2r cohort, 8 (38.1%) presented with EMD at diagnosis: 7 with CNS and 1 with non-CNS EMD. At relapse, 17 (80.9%) had EMD: 4 (19%) had CNS EMD, 9 (42.9%) had non-CNS EMD, and 4 (19%) had both. Isolated EMD was observed in 2 patients (11.8%) at first relapse and in 3 (17.6%) with multiple relapses. Given these findings, further study to evaluate this potential association between EMD and CRLF2r in R/R B-ALL is indicated. - Source: PubMed
Gava FlaviaYates BonnieSun ZhuoxinLi GraceO'Koren ChelseaAdhikari BiplovLugar SelinaShalabi HaneenMattison RyanTurkbey Evrim BYuan Constance MPaietta ElisabethWang Hao-WeiMullighan CharlesSilbert Sara KLitzow MarkShah Nirali N